Tags

Type your tag names separated by a space and hit enter

Evolution of Hydrogen Sulfide Therapeutics to Treat Cardiovascular Disease.
Circ Res. 2018 08 17; 123(5):590-600.CircR

Abstract

Hydrogen sulfide (H2S)-a potent gaseous signaling molecule-has emerged as a critical regulator of cardiovascular homeostasis. H2S is produced enzymatically by 3 constitutively active endogenous enzymes in all mammalian species. Within the past 2 decades, studies administering H2S-donating agents and the genetic manipulation of H2S-producing enzymes have revealed multiple beneficial effects of H2S, including vasodilation, activation of antiapoptotic and antioxidant pathways, and anti-inflammatory effects. More recently, the heightened enthusiasm in this field has shifted to the development of novel H2S-donating agents that exert favorable pharmacological profiles. This has led to the discovery of novel H2S-mediated signaling pathways. This review will discuss recently developed H2S therapeutics, introduce signaling pathways that are influenced by H2S-dependent sulfhydration, and explore the dual-protective effect of H2S in cardiorenal syndrome.

Authors+Show Affiliations

From the Cardiovascular Center of Excellence and Department of Pharmacology, LSU Health Science Center, New Orleans, LA.From the Cardiovascular Center of Excellence and Department of Pharmacology, LSU Health Science Center, New Orleans, LA.From the Cardiovascular Center of Excellence and Department of Pharmacology, LSU Health Science Center, New Orleans, LA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

30355137

Citation

Li, Zhen, et al. "Evolution of Hydrogen Sulfide Therapeutics to Treat Cardiovascular Disease." Circulation Research, vol. 123, no. 5, 2018, pp. 590-600.
Li Z, Polhemus DJ, Lefer DJ. Evolution of Hydrogen Sulfide Therapeutics to Treat Cardiovascular Disease. Circ Res. 2018;123(5):590-600.
Li, Z., Polhemus, D. J., & Lefer, D. J. (2018). Evolution of Hydrogen Sulfide Therapeutics to Treat Cardiovascular Disease. Circulation Research, 123(5), 590-600. https://doi.org/10.1161/CIRCRESAHA.118.311134
Li Z, Polhemus DJ, Lefer DJ. Evolution of Hydrogen Sulfide Therapeutics to Treat Cardiovascular Disease. Circ Res. 2018 08 17;123(5):590-600. PubMed PMID: 30355137.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evolution of Hydrogen Sulfide Therapeutics to Treat Cardiovascular Disease. AU - Li,Zhen, AU - Polhemus,David J, AU - Lefer,David J, PY - 2018/10/26/entrez PY - 2018/10/26/pubmed PY - 2019/10/1/medline KW - animals KW - cardiovascular diseases KW - nitric oxide SP - 590 EP - 600 JF - Circulation research JO - Circ Res VL - 123 IS - 5 N2 - Hydrogen sulfide (H2S)-a potent gaseous signaling molecule-has emerged as a critical regulator of cardiovascular homeostasis. H2S is produced enzymatically by 3 constitutively active endogenous enzymes in all mammalian species. Within the past 2 decades, studies administering H2S-donating agents and the genetic manipulation of H2S-producing enzymes have revealed multiple beneficial effects of H2S, including vasodilation, activation of antiapoptotic and antioxidant pathways, and anti-inflammatory effects. More recently, the heightened enthusiasm in this field has shifted to the development of novel H2S-donating agents that exert favorable pharmacological profiles. This has led to the discovery of novel H2S-mediated signaling pathways. This review will discuss recently developed H2S therapeutics, introduce signaling pathways that are influenced by H2S-dependent sulfhydration, and explore the dual-protective effect of H2S in cardiorenal syndrome. SN - 1524-4571 UR - https://www.unboundmedicine.com/medline/citation/30355137/Evolution_of_Hydrogen_Sulfide_Therapeutics_to_Treat_Cardiovascular_Disease_ DB - PRIME DP - Unbound Medicine ER -